Breast cancer biology blossoms in the clinic

1. Wickerham, D.L. et al. The initial results from NSABP protocol P-1: A clinical trial to determine the worth of tamoxifen for preventing breast cancer in women at increased risk. Proc. Amer. Soc. Clin. Oncol. 17, 2a (Abstract #3a) (1998).
2. Cummings, S.R. et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. Two-year findings from the multiple outcomes of raloxifene evaluations (MORE) trial. Proc. Amer. Soc. Clin. Oncol. 17, 2a (abstract # 3) (1998).
3. Jordan, V.C. et al. Incident primary breast cancers are reduced by raloxifene: integrated data from multicenter, double-blind, randomized trials in 12,000 postmenopausal women. Proc. Amer. Soc. CHn. Oncol. 17, 122a (Abstract #466) (1998).
4. Cobleigh, M.A. et al. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc. Amer. Soc. din. Oncol. 17, 97a (Abstract #376) (1998).
5. Slamon, D. et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER27MBC) markedly increases anti-cancer activity: A randomized, multinational controlled phase III trial. Proc. Amer. Soc. Clin. Oncol. 17, 98a (Abstract # 377) (1998).
6. Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. The Lancet 351, 1451−1467 (1998).
7. Grese, T.A. et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc. Natl. Acad. Sci. USA 94, 14105−14110 (1997). | Article | PubMed  | ChemPort |
8. Delmas, P.D. et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337, 1641−1647 (1997). | Article | PubMed  | ISI | ChemPort |
9. Reese, D.M. & Slamon, D. HER-2/NEU signal transduction in human breast and ovarian cancer. Stem Cells 15, 1−8 (1997). | PubMed  | ISI | ChemPort |
10. Newby, J.C., Johnston, S.R.D., Smith, I.E. & Dowset, M. Expression of epidermal growth factor receptor and c-ErbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res. 3, 1643−1651 (1997). | PubMed  | ISI | ChemPort |
11. Pietras, R.J. et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10, 2435−2446 (1995). | PubMed  | ISI | ChemPort |
12. Disis, M.L., Crabstein, K.H., Sleath, P.R. & Cheever, M.A. HER-2/Neu peptide vaccines elicit T cell immunity to the HER-2/Neu protein in patients with breast and ovarian cancer. Proc. Amer. Soc. Clin. Oncol. 17, 97a (Abstract #375) (1998).
13. Singh, J. et al. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the ErbB receptor subfamily of protein tyrosine kinases. J. Med. Chem. 40, 1130−1135 (1997). | Article | PubMed  | ISI | ChemPort |

	Top

	Top